Company intelligence / Profile preview

Onni Group

Ownership: Private
Development stage: Other

Overview

Onni Biotechnologies develops novel diagnostics for cancer and autoimmune diseases using TNF-family protein analysis, investigates immune cell interactions in cancer, and engineers natural killer cells for potential therapeutic use. Their work remains at the preclinical stage with ongoing collaborations and recent scientific publications.

Therapeutic areas: ImmunologyOncology
Modalities: Cell therapyDiagnostic assaySmall moleculeCRISPR-based therapy
Industry: Biotech

Partnerships

Business Finland support/fundingseeking foundation collaborations for innovation/research support

Beyond the preview

Go deeper on Onni Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Onni Group.

Explore the full profile